{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:27:39Z","timestamp":1791120459779,"version":"4.1.0"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 48-year-old woman with chemorefractory metastatic gastric cancer to the liver was treated in a phase I clinical trial with MetMAb, a monoclonal antibody targeting the Met tyrosine kinase receptor. The primary tumor had high MET gene polysomy and evidence for an autocrine production of hepatocyte growth factor, the growth factor ligand of Met. A complete response was obtained that lasted 2 years; the cancer recurred as a peritoneal deposit invading into the transverse colon and a gastrohepatic ligament node. Compassionate use of MetMAb therapy at recurrence achieved a mixed response: a partial response of the two initial lesions but with development of multiple new foci of carcinomatosis. Tissue and serum studies to evaluate the Met signaling pathway correlated with MetMAb treatment response initially and at the time of recurrence.<\/jats:p><jats:p>Significance: This research brief is the first to describe a durable complete response obtained with a molecularly targeted monoclonal antibody, MetMAb, to the receptor tyrosine kinase, Met, in a patient with chemorefractory metastatic gastric cancer. It is also the first to report biomarkers that predicted therapeutic response to Met inhibition. Cancer Discovery; 1(7); OF1\u2013OF7. \u00a92011 AACR.<\/jats:p><jats:p>Read the Commentary on this article by Feng and Ma, p. 550<\/jats:p><jats:p>This article is highlighted in the In This Issue feature, p. 539<\/jats:p>","DOI":"10.1158\/2159-8290.cd-11-0175","type":"journal-article","created":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T05:28:42Z","timestamp":1318310922000},"page":"573-579","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence"],"prefix":"10.1158","volume":"1","author":[{"given":"Daniel V. T.","family":"Catenacci","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Les","family":"Henderson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yuan","family":"Xiao","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal","family":"Patel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Yauch","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Hegde","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Zha","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Pandita","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Peterson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medicine, Section of Hematology\/Oncology and 2Department of Pathology, University of Chicago, Chicago, Illinois; and 3Genentech, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,12,13]]},"reference":[{"key":"2022060622172602300_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"2022060622172602300_bib2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N Engl J Med"},{"key":"2022060622172602300_bib3","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1158\/1078-0432.CCR-05-1418","article-title":"A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo","volume":"12","author":"Martens","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022060622172602300_bib4","author":"Salgia"},{"key":"2022060622172602300_bib5","first-page":"4717","article-title":"Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patient with advanced solid malignancies","volume-title":"Cancer Res","author":"Moss","year":"2011"},{"key":"2022060622172602300_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.7505","volume-title":"Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC","author":"Spigel","year":"2011"},{"key":"2022060622172602300_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/cbt.12.1.15747","article-title":"RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma","volume":"12","author":"Catenacci","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"2022060622172602300_bib8","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1073\/pnas.0508776103","article-title":"Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752","volume":"103","author":"Smolen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622172602300_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-291X(92)91548-5","article-title":"Frequent amplification of the c-met gene in scirrhous type stomach cancer","volume":"189","author":"Kuniyasu","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"2022060622172602300_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/JTO.0b013e3181ce3d1d","article-title":"High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer","volume":"5","author":"Go","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2022060622172602300_bib11","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060622172602300_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jcp.22333","article-title":"Lapatinib, a dual HER1\/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth","volume":"226","author":"Vazquez-Martin","year":"2011","journal-title":"J Cell Physiol"},{"key":"2022060622172602300_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1586\/era.10.226","article-title":"HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies","volume":"11","author":"Gajria","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"2022060622172602300_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.4161\/cc.4.5.1688","article-title":"Met activation and receptor dimerization in cancer: a role for the Sema domain","volume":"4","author":"Wickramasinghe","year":"2005","journal-title":"Cell Cycle"},{"key":"2022060622172602300_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1349-7006.2007.00640.x","article-title":"Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines","volume":"99","author":"Nakamura","year":"2008","journal-title":"Cancer Sci"},{"key":"2022060622172602300_bib16","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1158\/0008-5472.CAN-10-0436","article-title":"MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors","volume":"70","author":"Cepero","year":"2010","journal-title":"Cancer Res"},{"key":"2022060622172602300_bib17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022060622172602300_bib18","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1200\/JCO.2010.33.2742","article-title":"Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology","volume":"28","author":"Kris","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060622172602300_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"2022060622172602300_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.seminoncol.2011.01.013","article-title":"Molecular profiling of cancer-the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic","volume":"38","author":"Stricker","year":"2011","journal-title":"Semin Oncol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/1\/7\/573\/1812543\/573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/1\/7\/573\/1812543\/573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T13:46:05Z","timestamp":1713015965000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/1\/7\/573\/2438\/Durable-Complete-Response-of-Metastatic-Gastric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,1]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,12,13]]},"published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-11-0175","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,1]]}}}